@techreport{oai:mie-u.repo.nii.ac.jp:00012423,
 author = {大竹, 耕平 and OTAKE, Kohei},
 month = {May},
 note = {application/pdf, 予後不良な神経芽腫のマーカーを選出するため、2つの神経芽腫細胞株を用い、分化誘導を行い、分化した細胞、分化していない細胞からタンパク質を抽出した。Proteomics によりタンパク質の同定を行い、合計713種類のタンパク質が検出され、12種類のタンパク質が分化していない悪性度の高い神経芽腫の細胞のみに発現していた。このうち、ATP-dependent RNA helicase(DDX39A)に着目し、検証を行った。神経芽腫の予後との検討では神経芽腫の予後因子の一つであるMYCN増幅と共に有意に予後と相関を認め、DDX39Aの高発現群でoverall survivalが不良であった。, Shotgun proteomic analysis was performed in undifferentiated and ATRA-induced differentiated NB cells in vitro. An identified protein was verified by MRM and western blot analysis. Immunohistochemistry (IHC) was used to examine the expression of the identified protein in 33 primary NB tissues. Twelve proteins, including ATP-dependent RNA helicase (DDX39A), were only detected in undifferentiated NB cells. A peptide of DDX39A was detected at a significantly higher level in undifferentiated IMR-32 and LA-N-1 cells by MRM. Western blot analysis revealed that DDX39A expression was significantly higher in undifferentiated IMR-32 and LA-N-1 cells. IHC demonstrated that DDX39A was highly expressed in the primary tumor tissues of patients with poor prognosis, and univariate and multivariate survival analyzes showed that DDX39A expression could be an independent unfavorable prognostic factor. DDX39A is a potential biomarker for unfavorable NB using a proteomic approach., 2015年度～2016年度科学研究費補助金(若手研究(B))研究成果報告書, 15K20299},
 title = {再発・進行神経芽腫の予後改善を目指したプロテオミクスによる新規マーカーの検討},
 year = {2017}
}